new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.
Scarisbrick JJ., Quaglino P., Whittaker S., Bagot M., Guenova E., Papadavid E., Prince HM., Sanches JA., Miyashiro DR., Servitje O., Querfeld C., Akilov O., Arumainathan A., Bennett L., Battistella M., Benstead K., Berti E., Beylot-Barry M., Busschots A-M., Cowan R., Dummer R., Dunnill G., Estrach T., Evison F., Bashir A., Geskin L., Gru A., Guitart J., Herrera MC., Hodak E., Horwitz S., Jonak C., Klemke C-D., Knobler R., Mckay P., Marschalkó M., Massone C., Matin R., Mitteldorf C., Novoa R., Ortiz-Romero P., Pimpinelli N., Pujol RM., Ranki A., Vakeva L., Rieger KE., Stadler R., Trautinger F., Latzka J., Vermeer M., Wachsmuth R., Weatherhead S., Wehkamp U., Wobser M., Kim YH.
Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor overall survival (OS) of <5 years. Studies have found the current staging (IA-IVB) is inadequate for risk stratification. The PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study was launched in 2015 at 46 international expert MF/SS centers, prospectively collecting predefined data sets in patients with newly diagnosed MF/SS, to determine a cutaneous lymphoma IPI (CLIPI). Five hundred fifty-two patients with advanced stage MF/SS were recruited. The 5-year OS was 50.0% for stage IIB, 64.8% for stage IIIA, 43.9% for stage IIIB, 50.8% for stage IVA1, 25.9% for stage IVA2, and 36.9% for stage IVB. Factors at diagnosis associated with a significantly worse survival were N3 status (P < .001), age >60 years (P < .001), raised serum lactate dehydrogenase (P = .005), and large-cell transformation in skin (P = .006). Modeling these 4 independent risk factors into a CLIPI found that there was a worse OS in high- vs low-risk (P < .001), high- vs intermediate-risk (P = .002) and intermediate- vs low-risk (P = .010) groups. Five-year OS was 63.3%, 44.7%, and 18.3% in the low-, intermediate-, and high-risk groups, respectively. In this advanced stage cohort there was a low 5-year survival and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into risk groups has the potential to improve outcomes and aid optimal treatment selection. This trial was registered at www.ClinicalTrials.gov as #NCT02848274.